ClinicalTrials.gg
CompletedNCT03254108Updated Jul 28, 2021Results posted

Clinical Pharmacology Trial to Investigate the Dose of OPC-61815 Injection Equivalent to Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure

An interventional study of OPC-61815 injection 2mg and OPC-61815 injection 4mg in Congestive Heart Failure, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 20 Years to 85 Years. Per ClinicalTrials.gov, last updated 2021-07-28.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
61
Allocation
Randomized
Ages
20 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Heart Failure by Otsuka Holdings Co., Ltd. — none open to participants now, 1 under way, none of them phase 3. Heart Failure · Otsuka Holdings Co., Ltd..

Enrollment
9th of 16
61 · median 81
Started
2017
the only one that year
No phase
2 of 17
none open now
Registered
9th of 17
by date

Among the 17 studies in Heart Failure by Otsuka Holdings Co., Ltd., this one is the 9th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2017, is one of 2 with no phase, and was the 9th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

None of the 17 studies in Heart Failure by Otsuka Holdings Co., Ltd. is open now. The open studies under Heart Failure, anywhere →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 20 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies in Heart Failure by Otsuka Holdings Co., Ltd. as a file.
02

Study summary

The dose for intravenous administration of OPC-61815 achieving tolvaptan exposure equivalent to that for oral administration of tolvaptan 15-mg tablet will be investigated by administering OPC-61815 injection 2 to 16mg or tolvaptan 15-mg oral tablet to subjects with congestive heart failure.

03

Conditions studied

  • Congestive Heart Failure

Browse trials for

04

Who can participate

Ages eligible
20 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who are currently on treatment with any of the following diuretics

    • Loop diuretics equivalent to furosemide tablet or fine granules at a dose of 40 mg/day or higher
    • Concomitant use of a loop diuretic and a thiazide diuretic (including thiazide analogs) at any dose
    • Concomitant use of a loop diuretic and an aldosterone antagonist or potassium-sparing diuretic agent at any dose
  2. Subjects with congestive heart failure in whom lower limb edema, pulmonary congestion, and/or jugular venous distension due to volume overload is present
  3. Subjects who are currently hospitalized or who are able to be hospitalized during the trial

Exclusion criteria

Exclusion Criteria:

  1. Subjects with acute heart failure
  2. Subjects with a history of to any of ingredients of OPC-61815 or tolvaptan
  3. Subjects who are unable to sense thirst or who have difficulty with fluid intake
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    OPC-61815 injection 2mg

    Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 2 mg.

    Drug: OPC-61815 injection 2mg

  • Experimental
    OPC-61815 injection 4mg

    Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 4 mg.

    Drug: OPC-61815 injection 4mg

  • Experimental
    OPC-61815 injection 8mg

    Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 8 mg.

    Drug: OPC-61815 injection 8mg

  • Experimental
    OPC-61815 injection 16mg

    Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg.

    Drug: OPC-61815 injection 16mg

  • Active comparator
    Tolvaptan tablet 15mg

    Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo.

    Drug: Tolvaptan tablet 15mg

Interventions

  • Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 2 mg.

  • Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 4 mg.

  • Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 8 mg.

  • Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg.

  • Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo.

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration (Cmax) of OPC-41061 on Day 1

    Time frame: Baseline, 1, 1.5, 2, 4, 6, 12 24 hours after the start of administration of investigational drug

  2. Area Under the Concentration-time Curve From Time Zero to 24 Hours (AUC24h) on Day 1

    Time frame: Baseline, 1, 1.5, 2, 4, 6, 12 24 hours after the start of administration of investigational drug

07

Results

Posted Jul 28, 2021

Participant flow

Participant flow — Overall Study
MilestoneOPC-61815 Injection 2mgOPC-61815 Injection 4mgOPC-61815 Injection 8mgOPC-61815 Injection 16mgTolvaptan Tablet 15mg
Started1312121212
Received treatment1312121112
Completed131012119
Not completed02013
Withdrew: Adverse event02011
Withdrew: Ast/alt is increased to 3 times upper limit of normal or higher00002

Outcome measures

PrimaryMaximum Plasma Concentration (Cmax) of OPC-41061 on Day 1
Time frame:
Baseline, 1, 1.5, 2, 4, 6, 12 24 hours after the start of administration of investigational drug
Reported as:
Mean · ng/mL
Maximum Plasma Concentration (Cmax) of OPC-41061 on Day 1
ng/mLOPC-61815 Injection 2mgOPC-61815 Injection 4mgOPC-61815 Injection 8mgOPC-61815 Injection 16mgTolvaptan Tablet 15mg
Maximum Plasma Concentration (Cmax) of OPC-41061 on Day 141.4 ± 11.498.6 ± 43.7149 ± 61.7282 ± 96.0325 ± 194
PrimaryArea Under the Concentration-time Curve From Time Zero to 24 Hours (AUC24h) on Day 1
Time frame:
Baseline, 1, 1.5, 2, 4, 6, 12 24 hours after the start of administration of investigational drug
Reported as:
Mean · ng*h/mL
Area Under the Concentration-time Curve From Time Zero to 24 Hours (AUC24h) on Day 1
ng*h/mLOPC-61815 Injection 2mgOPC-61815 Injection 4mgOPC-61815 Injection 8mgOPC-61815 Injection 16mgTolvaptan Tablet 15mg
Area Under the Concentration-time Curve From Time Zero to 24 Hours (AUC24h) on Day 1356 ± 157983 ± 5631340 ± 5222400 ± 10302850 ± 1580

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) were collected from the start of IMP administration up to 15 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OPC-61815 Injection 2mg0/13 (0%)0/13 (0%)7/13 (53.8%)
OPC-61815 Injection 4mg0/12 (0%)1/12 (8.3%)7/12 (58.3%)
OPC-61815 Injection 8mg0/12 (0%)0/12 (0%)4/12 (33.3%)
OPC-61815 Injection 16mg0/11 (0%)0/11 (0%)8/11 (72.7%)
Tolvaptan Tablet 15mg0/12 (0%)0/12 (0%)10/12 (83.3%)
Most frequent serious events
Most frequent serious events
EventOPC-61815 Injection 2mgOPC-61815 Injection 4mgOPC-61815 Injection 8mgOPC-61815 Injection 16mgTolvaptan Tablet 15mg
Atrial fibrillationCardiac disorders0/131/120/120/110/12
EndocarditisInfections and infestations0/131/120/120/110/12
Most frequent other events
Showing 10 of 52
Most frequent other events
EventOPC-61815 Injection 2mgOPC-61815 Injection 4mgOPC-61815 Injection 8mgOPC-61815 Injection 16mgTolvaptan Tablet 15mg
Vessel puncture site reactionGeneral disorders0/132/120/120/110/12
HyperuricaemiaMetabolism and nutrition disorders0/130/120/120/112/12
Dry eyeEye disorders0/130/120/121/110/12
Infusion site extravasationGeneral disorders0/130/120/121/110/12
NasopharyngitisInfections and infestations0/130/120/121/110/12
Vascular access site painInjury, poisoning and procedural complications0/130/120/121/110/12
Blood creatinine increasedInvestigations0/130/121/121/110/12
Blood urea increasedInvestigations0/130/121/121/111/12
Back painMusculoskeletal and connective tissue disorders0/130/120/121/110/12
HeadacheNervous system disorders0/131/120/121/110/12

Baseline characteristics

Safety Analysis Set: all subjects treated with the investigational medicinal product (IMP) at least once

Age, Continuous
Age, Continuous(years)OPC-61815 Injection 2mgOPC-61815 Injection 4mgOPC-61815 Injection 8mgOPC-61815 Injection 16mgTolvaptan Tablet 15mgTotal
Mean73.7 ± 9.574.5 ± 11.972.2 ± 9.977.9 ± 3.874.8 ± 8.974.6 ± 9.1
Sex: Female, Male
Sex: Female, Male(Participants)OPC-61815 Injection 2mgOPC-61815 Injection 4mgOPC-61815 Injection 8mgOPC-61815 Injection 16mgTolvaptan Tablet 15mgTotal
Female5453219
Male88781041
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)OPC-61815 Injection 2mgOPC-61815 Injection 4mgOPC-61815 Injection 8mgOPC-61815 Injection 16mgTolvaptan Tablet 15mgTotal
Asian131212111260
Region of Enrollment
Region of Enrollment(Participants)OPC-61815 Injection 2mgOPC-61815 Injection 4mgOPC-61815 Injection 8mgOPC-61815 Injection 16mgTolvaptan Tablet 15mgTotal
Japan131212111260
08

Study locations

1 site
  • Kanto, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article Publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Apr 2018, 5 months.

Results were first posted in Jul 2021, 3 years 3 months after primary completion.

Of 236 industry-sponsored interventional studies with no phase under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 62. This study's 5 months is below that.

Counting every sponsor, half of 1,354 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2017
First posted
Aug 18, 2017
StartActual
Nov 6, 2017
Primary completionActual
Apr 14, 2018
CompletionActual
Apr 24, 2018
Results first posted
Jul 28, 2021
Last update
Jul 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03254108
Responsible party
Sponsor
First posted
Aug 18, 2017
Start date
Nov 6, 2017
Primary completion
Apr 14, 2018
Completion
Apr 24, 2018
Results posted
Jul 28, 2021
Last update
Jul 28, 2021

Study contacts

Hiroaki Ono
study director · Otsuka Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: OPC-61815

Start the discussion